Repligen Corporation Announced BioMarin Pharmaceutical Acquired Assets in HDAC Inhibitor Program

Details

Repligen Press Release

BioMarin Press Release

FARA Press Release:

pdf/news/2014/FARA-PressRelease01-21-2014.pdf